You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility prnasia
January 18, 2022
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by South Korea's Ministry...
ImmuneOncia, WuXi Biologics partner for bispecific antibody development Pharmaceutical-Technology
December 30, 2021
ImmuneOncia Therapeutics has signed a Memorandum of Understanding (MoU) with WuXi Biologics to develop and manufacture bispecific antibody, IOH-001.
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate prnasia
August 03, 2021
WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the ...
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility prnasia
July 27, 2021
WuXi Biologics announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany.
WuXi Biologics Receives Manufacturing License from German Health Authorities contractpharma
July 27, 2021
The inspections comprised areas of cGMP manufacturing required for receiving the permit, as well as commercial production approval.
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership prnasia
May 27, 2021
WuXi Biologics, a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract ...
Duality Biologics Completed $90 Million Series B Financing prnasia
May 20, 2021
Duality Biologics, an innovative biotech company, announced the completion of $90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested by YUNION Healthcare Fund, Huagai Capital ...
WuXi Biologics, WuXi STA Establish WuXi XDC JV contractpharma
May 17, 2021
WuXi Biologics and WuXi STA, a subsidiary of WuXi AppTec, established a joint venture company named WuXi XDC to provide contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs). Dr. Jimmy (Jincai) Li was ...
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services prnasia
May 14, 2021
WuXi Biologics, a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end contract development ...
2020 Results Record High Despite a Challenging Year CHhIChina
March 24, 2021
WuXi Biologics announces its audited annual results for the year ended December 31, 2020.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page